Bill et al. [10] described 172 patients with KMT2A-rearranged AML, classified as intermediate-risk KMT2A::MLLT3 or as having adverse-risk rearrangements different from KMT2A::MLLT3, according to the ELN2017 classification [33]. This evidence concerns the gene MLLT3 and acute myeloid leukemia.